Rare Disease Day Around the NMD4C Community
Rare Disease Day is an opportunity to bring together communities of researchers, health care providers and patients under a unified theme. As a network which serves a rare disease community, we wish to promote the NMD activities that will take place on Rare Disease Day. In 2021 there is more opportunity to attend and get involved than ever before due to the increasing frequency of remotely accessible and virtual events!
Here are some of the upcoming Rare Disease Day 2021 events within our network:
- Jesse’s Journey will run a social media campaign throughout all February, profiling four families (one per week) for people to share and help raise awareness of Duchenne muscular dystrophy. Visit Jesse’s Journey’s website in the next weeks for more information.
- The Canadian Organization for Rare Disease (CORD) will be encouraging the Duchenne community to attend their Conference in early March titled “From Draft to Action Plan” on March 9-10, 2021 from 11am to 2pm EST.
- The Groupe de recherche interdisciplinaire en maladies neuromusculaires (GRIMN) will host an regional French event on February 25th 2021 called “Rare et fréquent, c’est possible!” in collaboration with the Centre intersectoriel en santé durable (CISD), the CIUSSS du Saguenay-Lac-Saint-Jean and CORAMH in which a section will focus on neuromuscular diseases. Details will be published on the GRIMN facebook page :
Are you organizing a Rare Disease Day webinar, a conference, a workshop or any other activity that could be of interest to other NMD4C members? Send us information about your Rare Disease Day activities to the following address: . The network will be pleased to share the various activities of Rare Disease Day with our members.
Together we can show how the neuromuscular community is engaging in Rare Disease Day!
Return to the February 2021 Newsletter
Read next...
New Publication from the NMD4C Clinical Trial Network Strengthens Trial Capacity in Canada
We are pleased to share a new publication from the NMD4C Clinical Trial Network led by Kerri Lynn Schellenberg, Homira Osman, Maria Masnata, Rhiannon Hicks, Corinne Kagan, Ana Stosic, Stacey Lintern, Erin Beattie, Drs. Hanns Lochmüller, Craig Campbell, and Jean K Mah. This work focuses on the implementation of a coordinated Canadian neuromuscular clinical trial network to enhance trial readiness, capacity, and access in rare disease research.
Canadian-Led Phase II Studies Advance Vamorolone Evidence in Duchenne Muscular Dystrophy
NMD4C investigators contributed to two phase II studies evaluating vamorolone in boys with Duchenne muscular dystrophy across early childhood and adolescence, demonstrating safety, favorable pharmacokinetics, and potential efficacy. Led by Dr. Jean Mah and conducted across Canadian clinical trial sites with national and industry collaborators, the findings supported Health Canada approval of vamorolone as the first treatment for DMD in Canada. Leaders from both the clinical and patient advocacy communities, including Defeat Duchenne Canada, highlighted the impact of collaboration among patients, families, clinicians, and researchers in advancing care and improving access to new therapies.
Advancing AFC in Neuromuscular Medicine: Program Launch & September Workshop
The Royal College has approved National Training Standards for the AFC in Neuromuscular Medicine, creating a formal pathway to recognize enhanced competence with the DRCPSC credential. This designation establishes a national training standard, supports portable certification, and strengthens clinical capacity across Canada. PGME offices can now apply to offer accredited AFC programs, with a goal of five programs submitting applications by the end of 2026.